Edition:
United Kingdom

Cantel Medical Corp (CMD.N)

CMD.N on New York Stock Exchange

97.58USD
20 Sep 2018
Change (% chg)

$0.24 (+0.25%)
Prev Close
$97.34
Open
$97.51
Day's High
$98.43
Day's Low
$96.93
Volume
17,463
Avg. Vol
89,478
52-wk High
$130.92
52-wk Low
$85.00

Latest Key Developments (Source: Significant Developments)

Cantel Expands Its Life Sciences Portfolio Through Acquisition Of Stericycle's Controlled Environmental Solutions Business
Friday, 3 Aug 2018 

Aug 3 (Reuters) - Cantel Medical Corp ::CANTEL EXPANDS ITS LIFE SCIENCES PORTFOLIO THROUGH ACQUISITION OF STERICYCLE'S CONTROLLED ENVIRONMENTAL SOLUTIONS BUSINESS.CANTEL MEDICAL CORP - CANTEL ANTICIPATES ACQUISITION TO BE ACCRETIVE TO NON-GAAP EARNINGS PER SHARE IN FISCAL YEAR ENDING JULY 31, 2019 AND BEYOND.CANTEL MEDICAL CORP - DEAL FOR $17.0 MILLION ON A CASH-FREE AND DEBT-FREE BASIS.CANTEL MEDICAL - EXPECTS DEAL TO BE ACCRETIVE TO GAAP EARNINGS PER SHARE IN FISCAL YEAR ENDING JULY 31, 2020 AND BEYOND.  Full Article

Cantel Medical Corp Chairman Charles Diker Reports Sale Of 10,000 Shares
Wednesday, 17 Jan 2018 

Jan 17 (Reuters) - Cantel Medical Corp ::CANTEL MEDICAL CORP CHAIRMAN CHARLES DIKER REPORTS OPEN MARKET SALE OF 10,000 SHARES OF CO'S COMMON STOCK ON JAN 16 AT $110.96 PER SHARE - SEC FILING.  Full Article

Cantel Medical Reports Record Financial Results For Q1 Fiscal Year 2018
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - Cantel Medical Corp ::Q1 SALES ROSE 13.3 PERCENT TO $212.8 MILLION.Q1 NON-GAAP EARNINGS PER SHARE $0.57.Q1 GAAP EARNINGS PER SHARE $0.55.Q1 REVENUE VIEW $207.7 MILLION -- THOMSON REUTERS I/B/E/S.Q1 EARNINGS PER SHARE VIEW $0.54 -- THOMSON REUTERS I/B/E/S.  Full Article

Cantel Medical Q3 non-GAAP earnings per share $0.51
Thursday, 8 Jun 2017 

June 8 (Reuters) - Cantel Medical Corp ::Cantel Medical reports financial results for the third quarter ended April 30, 2017.Q3 non-GAAP earnings per share $0.51.Q3 GAAP earnings per share $0.42.Q3 earnings per share view $0.51 -- Thomson Reuters I/B/E/S.Q3 revenue $192.1 million versus I/B/E/S view $193.8 million.Cantel Medical Corp says "we expect further restructuring costs to occur in Q4 of fiscal 2017".Cantel Medical Corp says order intake remained strong in q3, and backlog ended at record level for fourth consecutive quarter.  Full Article

BRIEF-Cantel Medical Receives FDA 510(K) Clearance To Market Advantage Plus® Pass-Thru Automated Endoscope Reprocessor

* CANTEL MEDICAL RECEIVES FDA 510(K) CLEARANCE TO MARKET ADVANTAGE PLUS® PASS-THRU AUTOMATED ENDOSCOPE REPROCESSOR Source text for Eikon: Further company coverage: